Foreign Collusion, Naked Shorting (Counterfeiting) & Money Laundering — All Illicit Wealth
Breakwater Trading sues JPMorgan for alleged manipulation of prices of US Treasury futures
Maria Nikolova
FinanceFeeds, 6 May 2020
Breakwater Trading LLC has launched a civil lawsuit against JPMorgan Chase & Co. (NYSE:JPM), JP Morgan Clearing Corp., JP Morgan Securities LLC, and JP Morgan Securities LLC, accusing them of manipulating the US Treasuries futures market. The complaint, seen by FinanceFeeds, was filed on May 5, 2020, with the New York Southern District Court.
If You Had Bought Nymox Pharmaceutical (NASDAQ:NYMX) Shares Five Years Ago You’d Have Made 91%
Simply Wall St, 05 May 2020
In late January 2021, GameStop experienced a once-in-a-decade squeeze that has captivated the world’s attention. It was a premeditated and programmatic exercise, orchestrated by coordinated stock and option buying across the retail and professional community, resulting in large institutional entities losing billions of dollars. Investment houses with significant short positions did not expect a stock with GameStop’s fundamental profile to increase +2,500% in price over less than three weeks; therefore, they did not have the controls in place to handle the incredible levels of stock and call option purchases. The frenzy drew comments from the White House, provoked a social media crackdown, caused brokerage units to restrict trading, and has led to a Congressional hearing on GameStop on Thursday, February 18th.
Continue reading “Article: If You Had Bought Nymox Pharmaceutical (NASDAQ:NYMX) Shares Five Years Ago You’d Have Made 91%”
Wirecard sues Financial Times over investigative reports
Straits Times (Singapore), 29 March 2019
Wirecard has filed a suit at the Munich regional court against both the FT and its reporter, Dan McCrum, seeking a ruling on the merits of its case. If successful, the company would then press for monetary redress.
Comment: Use the tag cloud to find other articles about Dan McCrum, suspected to be in collusion with naked short sellers.
Sell Microvision: Nothing Left To Be Optimistic About
SeekingAlpha.com, 29 January 2020
Summary: Unsustained purchase orders have crushed sales.
Comment: If lying were illegal these people would be in jail. Known basher in league with naked short sellers.
| May 05, 2020 | 0.6300 | 0.7300 | 0.5700 | 0.5800 | 0.5800 | 29,745,000 |
| May 04, 2020 | 0.5200 | 0.5300 | 0.5000 | 0.5200 | 0.5200 | 1,597,600 |
Comment: NOW LOOK AT THE NEWS Just who would sell all that stock on that GREAT news (only a naked short seller TRAPPED).
Aristides Capital LLC closes position in NLTX / Neoleukin Therapeutics, Inc
Fintel, 15 May 2020
Aristides Capital LLC has filed a 13F-HR form disclosing ownership of 0 shares of Neoleukin Therapeutics, Inc. (US:NLTX) with total holdings valued at $0 USD as of 2020-03-31. Aristides Capital LLC had filed a previous 13F-HR on 2020-02-13 disclosing 13,900 shares of Neoleukin Therapeutics, Inc. at a value of $171,000 USD. This represents a change in shares of -100.00 percent and a change in value of -100.00 percent during the quarter. Other investors with closed positions include Visium Asset Management, LP, Great Point Partners Llc, Perceptive Advisors Llc, Acuta Capital Partners, Llc, and Nomura Asset Management Co Ltd.
Continue reading “Article: Aristides Capital LLC closes position in NLTX / Neoleukin Therapeutics, Inc”
Wall Street Recommends Buying These 2 Falling Knives
Alberto Abaterusso
Guru Focus, 13 April 2020
Sell-side analysts on Wall Street recommend to buy shares of Stemline Therapeutics Inc (NASDAQ:STML) and KalVista Pharmaceuticals Inc (NASDAQ:KALV), even though their share prices have lost more than 59% over the past 52 weeks through April 10. Due to such tumbles, these stocks are known as falling knives.
Summit Therapeutics (SMMT) Receives a Buy from H.C. Wainwright
Austin Angelo
AnalystRatings, 1 May 2020
H.C. Wainwright analyst Ed Arce maintained a Buy rating on Summit Therapeutics (SMMT – Research Report) today and set a price target of $4.00. The company’s shares closed last Thursday at $3.75.
According to TipRanks.com, Arce is a 5-star analyst with an average return of 14.2% and a 41.9% success rate. Arce covers the Healthcare sector, focusing on stocks such as Entasis Therapeutics Holdings, Madrigal Pharmaceuticals, and Collegium Pharmaceutical.
H.C. Wainwright Keeps Their Buy Rating on Insmed (INSM)
Jason Carr
AnalystRatings, 1 May 2020
H.C. Wainwright analyst Andrew Fein maintained a Buy rating on Insmed (INSM – Research Report) today and set a price target of $52.00. The company’s shares closed last Thursday at $23.00.
According to TipRanks.com, Fein is a 5-star analyst with an average return of 7.7% and a 46.1% success rate. Fein covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Constellation Pharmaceuticals, and Proteostasis Therapeutics.
H.C. Wainwright Sticks to Their Buy Rating for Pluristem (PSTI)
Christine Brown
SmarterAnalyst, 1 May 2020
In a report released today, Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on Pluristem (PSTI), with a price target of $15.50. The company’s shares closed last Thursday at $9.17.
According to TipRanks.com, Ramakanth is a 1-star analyst with an average return of -0.7% and a 36.0% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Diffusion Pharmaceuticals, IntelGenx Technologies, and Corvus Pharmaceuticals.
H.C. Wainwright Keeps a Buy Rating on CareDx (CDNA)
Christine Brown
SmarterAnalyst, 1 May 2020
In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on CareDx (CDNA), with a price target of $40.00. The company’s shares closed last Thursday at $25.38.
According to TipRanks.com, Chen is a 5-star analyst with an average return of 14.1% and a 43.3% success rate. Chen covers the Healthcare sector, focusing on stocks such as Interpace Diagnostics Group, HTG Molecular Diagnostics, and EyePoint Pharmaceuticals.
Comment: This company is at risk of collusion between a placement agent and naked short sellers.
Business Insider, 30 April 2020
David Einhorn of Greenlight Capital has again taken to Twitter to call out Tesla’s accounting practices in a message directed at CEO Elon Musk.
“Dear Elon, I guess the offer of a factory tour was never serious,” Einhorn, a long-time Tesla bear and short-seller, tweeted Thursday. “I remain curious about your accounts receivable.”
Shares of Tesla pared gains from earlier in the day and traded down as much as 3% following Einhorn’s comments.
Co-Diagnostics Inc. [CODX] stock Reiterated by H.C. Wainwright analyst, price target now $20
Brandon Evans
DBT News, 30 April 2020
Co-Diagnostics Inc. [NASDAQ: CODX] traded at a low on 04/29/20, posting a -8.57 loss after which it closed the day’ session at $12.37. The results of the trading session contributed to over 5099148 shares changing hands. Over the past one week, the price volatility of Co-Diagnostics Inc. stands at 10.98% while the volatility over the past one month is 12.61%.
The market cap for CODX stock reached $332.63 million, with 26.89 million shares outstanding and 20.80 million shares in the current float. Compared to the average trading volume of 12.82M shares, CODX reached a trading volume of 5099148 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Comment: This company is at risk of collusion between a placement agent and naked short sellers.
RELATED:
H.C. Wainwright Keeps Their Hold Rating on PDS Biotechnology (PDSB)
Ryan Adist
SmarterAnalyst, 30 April 2020
H.C. Wainwright analyst Joseph Pantginis maintained a Hold rating on PDS Biotechnology (PDSB) today. The company’s shares closed last Wednesday at $0.95, close to its 52-week low of $0.62.
According to TipRanks.com, Pantginis is a 5-star analyst with an average return of 14.5% and a 43.7% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Lineage Cell Therapeutics, and Iovance Biotherapeutics.
Comment: This company is at risk of collusion between a placement agent and naked short sellers.
Vertex Pharmaceuticals (VRTX) Receives a Buy from H.C. Wainwright
Austin Angelo
SmarterAnalyst, 30 April 2020
In a report released today, Andrew Fein from H.C. Wainwright maintained a Buy rating on Vertex Pharmaceuticals (), with a price target of $295.00. The company’s shares closed last Wednesday at $251.05.
According to TipRanks.com, Fein is a 5-star analyst with an average return of 8.9% and a 48.1% success rate. Fein covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Constellation Pharmaceuticals, and Proteostasis Therapeutics.
THE DOLLAR HAS NO INTRINSIC VALUE : DO YOUR ASSETS?
